Skip to main content
main-content

Oncology news

08-02-2017 | Gastrointestinal cancer | Highlight | Article

Editor's pick

Adjuvant gemcitabine plus capecitabine ‘new standard of care’ for resected pancreatic cancer

Adding capecitabine to gemcitabine in the adjuvant setting significantly improves overall survival in patients with resected pancreatic ductal adenocarcinoma, the ESPAC-4 trial shows.

Source:

Lancet 2017; Advance online publication

10-02-2017 | Gastrointestinal cancer | News | Article

No role for bevacizumab in localized esophagogastric cancer

Phase III trial results indicate that the addition of bevacizumab to peri-operative chemotherapy does not improve the outcomes of patients with resectable esophagogastric adenocarcinoma and may even be associated with impaired wound healing.

Source:

Lancet Oncol 2017; Advance online publication

07-02-2017 | HBV | News | Article

Simple model predicts indeterminate nodule progression in HBV-related cirrhosis

South Korean researchers have developed a risk score based on routine baseline clinical data that can assess the risk of progression to hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis harboring indeterminate nodules.

Source:

Am J Gastroenterol 2016; Advance online publication

06-02-2017 | Lung cancer | News | Article

News in brief

US lung cancer screening rates low among high-risk smokers

The uptake of low-dose computed tomography lung cancer screening by heavy current and former smokers remains low despite the recommendations of the United States Preventive Services Task Force.

03-02-2017 | Oncology | News | Article

Editor's pick

Azathioprine linked to increased myeloid neoplasm risk

Azathioprine sodium exposure in patients with autoimmune disorders is associated with an elevated risk of developing myeloid neoplasms, shows a chart review published in JAMA Oncology.

Source:

JAMA Oncol 2017; Advance online publication

KEYNOTE-045 Supports Pembrolizumab For Platinum-Refractory Urothelial Cancer

Patients with urothelial carcinoma resistant to or progressing on platinum chemotherapy may have longer overall survival with pembrolizumab than conventional chemotherapy agents

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage

medwireNews@ESMO2016

medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits